These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 30089726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.
    Rehman T, Karp PH, Tan P, Goodell BJ, Pezzulo AA, Thurman AL, Thornell IM, Durfey SL, Duffey ME, Stoltz DA, McKone EF, Singh PK, Welsh MJ.
    J Clin Invest; 2021 Aug 16; 131(16):. PubMed ID: 34166230
    [Abstract] [Full Text] [Related]

  • 3. Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor.
    Chang EH, Tang XX, Shah VS, Launspach JL, Ernst SE, Hilkin B, Karp PH, Abou Alaiwa MH, Graham SM, Hornick DB, Welsh MJ, Stoltz DA, Zabner J.
    Int Forum Allergy Rhinol; 2015 Feb 16; 5(2):178-81. PubMed ID: 25363320
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M, Krishan A, Patel S, Sinha IP, Southern KW.
    Cochrane Database Syst Rev; 2019 Jan 07; 1(1):CD009841. PubMed ID: 30616300
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.
    Char JE, Wolfe MH, Cho HJ, Park IH, Jeong JH, Frisbee E, Dunn C, Davies Z, Milla C, Moss RB, Thomas EA, Wine JJ.
    PLoS One; 2014 Jan 07; 9(2):e88564. PubMed ID: 24520399
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD.
    Ann Am Thorac Soc; 2020 Feb 07; 17(2):212-220. PubMed ID: 31604026
    [Abstract] [Full Text] [Related]

  • 11. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY, Zhang S, Lazrak A, Grayson JW, Peña Garcia JA, Skinner DF, Lim DJ, Mackey C, Banks C, Matalon S, Woodworth BA.
    Int Forum Allergy Rhinol; 2019 Jan 07; 9(1):100-105. PubMed ID: 30152192
    [Abstract] [Full Text] [Related]

  • 12. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.
    Cochrane Database Syst Rev; 2015 Mar 26; (3):CD009841. PubMed ID: 25811419
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group.
    N Engl J Med; 2011 Nov 03; 365(18):1663-72. PubMed ID: 22047557
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary Ionocytes Regulate Airway Surface Liquid pH in Primary Human Bronchial Epithelial Cells.
    Luan X, Henao Romero N, Campanucci VA, Le Y, Mustofa J, Tam JS, Ianowski JP.
    Am J Respir Crit Care Med; 2024 Sep 15; 210(6):788-800. PubMed ID: 38573173
    [Abstract] [Full Text] [Related]

  • 17. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
    Ludovico A, Moran O, Baroni D.
    Int J Mol Sci; 2022 Sep 27; 23(19):. PubMed ID: 36232697
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM, VX16-659-101 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1599-1611. PubMed ID: 30334693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.